ACAD
18.26
+0.71
+4.05%
AEMD
4.84
-0.56
-10.37%
APRI
1.14
-0.03
-2.56%
ARNA
1.52
+0.05
+3.40%
ATEC
0.205
-0.004
-1.914%
CNAT
1.73
+0.08
+4.85%
CRXM
0.2
-0.03
-12.28%
CYTX
0.133
0.00
0.00%
DXCM
56.12
-0.13
-0.23%
GNMK
4.78
-0.26
-5.16%
HALO
7.54
+0.11
+1.48%
ILMN
142.72
+4.26
+3.08%
INNV
0.06
+0.01
+20.00%
INO
6.27
+0.08
+1.29%
ISCO
2.44
-0.17
-6.51%
ISIS
57.56
0.00
0.00%
LGND
85.97
+0.18
+0.21%
LPTN
0.156
+0.00
+0.0644%
MBVX
0.53
0.00
+0.23%
MEIP
1.04
-0.02
-1.89%
MNOV
4.19
-0.03
-0.71%
MRTX
20.11
+0.72
+3.71%
MSTX
0.256
+0.021
+8.7197%
NBIX
36.04
+0.67
+1.89%
NUVA
39.12
-2.7
-6.46%
ONCS
1.68
+0.17
+11.26%
ONVO
1.89
-0.04
-2.07%
OREX
1.64
-0.01
-0.61%
OTIC
14.33
+0.37
+2.65%
QDEL
14.99
-0.29
-1.90%
RCPT
231.96
0.00
0.00%
RGLS
5.84
-0.01
-0.17%
RMD
57.88
+0.76
+1.33%
SCIE
0.001
+0.00
+14.2857%
SPHS
1.58
+0.01
+0.64%
SRNE
5.52
+0.63
+12.88%
TROV
3.76
-0.15
-3.84%
VICL
0.305
-0.015
-4.6904%
VOLC
18
0.00
0.00%
ZGNX
9.79
+0.27
+2.84%
ACAD
18.26
+0.71
+4.05%
AEMD
4.84
-0.56
-10.37%
APRI
1.14
-0.03
-2.56%
ARNA
1.52
+0.05
+3.40%
ATEC
0.205
-0.004
-1.914%
CNAT
1.73
+0.08
+4.85%
CRXM
0.2
-0.03
-12.28%
CYTX
0.133
0.00
0.00%
DXCM
56.12
-0.13
-0.23%
GNMK
4.78
-0.26
-5.16%
HALO
7.54
+0.11
+1.48%
ILMN
142.72
+4.26
+3.08%
INNV
0.06
+0.01
+20.00%
INO
6.27
+0.08
+1.29%
ISCO
2.44
-0.17
-6.51%
ISIS
57.56
0.00
0.00%
LGND
85.97
+0.18
+0.21%
LPTN
0.156
+0.00
+0.0644%
MBVX
0.53
0.00
+0.23%
MEIP
1.04
-0.02
-1.89%
MNOV
4.19
-0.03
-0.71%
MRTX
20.11
+0.72
+3.71%
MSTX
0.256
+0.021
+8.7197%
NBIX
36.04
+0.67
+1.89%
NUVA
39.12
-2.7
-6.46%
ONCS
1.68
+0.17
+11.26%
ONVO
1.89
-0.04
-2.07%
OREX
1.64
-0.01
-0.61%
OTIC
14.33
+0.37
+2.65%
QDEL
14.99
-0.29
-1.90%
RCPT
231.96
0.00
0.00%
RGLS
5.84
-0.01
-0.17%
RMD
57.88
+0.76
+1.33%
SCIE
0.001
+0.00
+14.2857%
SPHS
1.58
+0.01
+0.64%
SRNE
5.52
+0.63
+12.88%
TROV
3.76
-0.15
-3.84%
VICL
0.305
-0.015
-4.6904%
VOLC
18
0.00
0.00%
ZGNX
9.79
+0.27
+2.84%
Home » Archive by Category

Syndication

Purchasing & Imports Specialist (Carlsbad)

February 10, 2016 – 4:36 pm

POSITION: PURCHASING & IMPORTS SPECIALIST
SUMMARY:
Under the direct supervision of the President/Manager of Operations, the Purchasing & Imports Specialist is responsible for purchasing products and tracking the shipments from international supplie […]

Genomic Health Announces 2016 Financial Outlook and Provides 2015 Fourth Quarter and Year-End Financial Results

February 10, 2016 – 2:05 pm

Expects to Deliver Double-Digit Test and Revenue Growth in 2016Plans to Launch First Liquid Biopsy Test Mid-2016Conference Call Today at 4:30 p.m. ET

REDWOOD CITY, Calif., Feb. 10, 2016 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2015.

Revenue was $74.5 million in the fourth quarter of 2015, compared with $69.1 million in the fourth quarter of 2014, an increase of 8 percent. On a constant currency basis, revenue increased 9 percent compared with the same period in the prior year.

U.S. revenue was $63.9 million in the fourth quarter of 2015, an increase of 9 percent compared with the same period in the prior year. International revenue was $10.6 million in the fourth quarter of 2015, compared with $10.3 million a year ago. International revenue was reduced by $0.6 million from foreign exchange rate differences due to the stronger dollar as compared to a year ago.

Revenue was $286.8 million in the full year 2015, compared with $275.7 million in 2014, an increase of 4 percent. International revenue for the full year 2015 was $41.4 million, compared with $45.0 million a year ago. For the year ended December 31, 2015, international revenue was reduced by approximately $3.0 million from foreign exchange rate differences due to the stronger dollar as compared to a year ago.

More than 107,030 Oncotype DX® test results were delivered for the year ended December 31, 2015, an increase of 12 percent, compared with more than 95,610 test results delivered in 2014. In the fourth quarter of 2015, more than 27,730 Oncotype DX test results were delivered, an increase of 12 percent, compared with more than 24,770 test results delivered in the same period in 2014. Prostate tests delivered in the United States for the full year grew 75 percent compared to the prior year and represented approximately 8 percent of total test volume in 2015. International tests delivered in the full-year grew 19 percent compared to the prior year and represented approximately 21 percent of total test volume in 2015.

“We expect the strong momentum generated across our business in 2015, combined with new compelling global prospective outcomes evidence for the Oncotype DX breast cancer test and recent Medicare coverage for the Oncotype DX prostate cancer test, to lead to double-digit test and revenue growth in 2016,” said Kim Popovits, Chairman of the Board, Chief Executive Officer and President of Genomic Health. “Additionally, we are excited to continue our impact in making cancer care smarter by launching our first liquid biopsy test, Oncotype SEQ™, in mid-2016.”

Operating loss for the fourth quarter narrowed to $3.5 million compared with $6.0 million for the fourth quarter of 2014. Net loss was $3.2 million for the fourth quarter of 2015 and includes a $0.8 million tax credit in the quarter resulting from a change in fair value of the company’s investment in a marketable security. Basic and diluted net loss per share was $0.10 for the fourth quarter of 2015 compared with basic and diluted net loss per share of $0.20 for the same period in 2014.

Additional Year-End 2015 Financial Results

Operating loss was $34.5 million for the year ended December 31, 2015, compared with an operating loss of $23.6 million for the year ended December 31, 2014. The operating loss for the year ended December 31, 2015 includes a non-recurring first quarter charge of $5.5 million in R&D associated with the wind-down of a breast cancer collaboration.

Net loss was $33.8 million for the year ended December 31, 2015, compared with a net loss of $24.6 million for the year ended December 31, 2014. Basic and diluted net loss per share was $1.04 for the year ended December 31, 2015, compared with a basic and diluted net loss per share of $0.78 for the year ended December 31, 2014.

Cash and cash equivalents and short-term investments at December 31, 2015 were $76.8 million, excluding the fair value of the company’s investment in a marketable security of $18.1 million, compared with $103.7 million at December 31, 2014. 

2016 Financial Guidance

“In 2016 we plan to deliver double-digit test and revenue growth and improve our net loss, while delivering positive EBITDA*,” said Brad Cole, Chief Operating Officer and Chief Financial Officer of Genomic Health. “We expect our net loss in the first half of the year to be within the full year loss guidance of $12 to $18 million and to move toward profitability in the second half of the year.”

The company is providing the following financial guidance for the full year ending December 31, 2016:

  • Total revenue of $320 to $335 million, representing growth of between 12 and 17 percent compared to 2015;
  • Net loss between $12 and $18 million at the mid-point of revenue guidance, excluding the effect of the company’s investment in a marketable security, or basic net loss per share of between $0.37 and $0.55; and
  • Oncotype DX tests delivered of 117,500 to 121,000, representing growth of between 10 and 13 percent compared to 2015.

*EBITDA, or earnings before interest, taxes, depreciation and amortization, is a non-GAAP term.

Recent Business Highlights:

Oncotype DX Commercial Progress

  • Implemented new enterprise-wide platform (ERP) to add novel capabilities and provide the ability to scale the company’s growing business.
  • Expanded coverage of the Oncotype DX breast cancer test for patients with 1-3 positive nodes to include 11 million additional lives through new policies with Health Net, Blue Cross Blue Shield of Florida and Independent Blue Cross. This brings the total number of node-positive covered lives to more than 161 million U.S. lives.
  • Received positive reimbursement decisions for the Oncotype DX breast cancer test in four additional regions of Spain bringing the total number of ex-U.S. lives covered to 196 million.
  • The Centers for Medicare and Medicaid Services (CMS), which administers the Medicare program, issued its final Clinical Laboratory Fee Schedule (CLFS) for 2016, which will allow the Medicare Administrative Contractor (MAC) to continue to set payment for the Oncotype DX colon cancer test through 2016, as has been done since initiation of coverage in 2011.

 Pipeline, Presentations and Publications

  • Announced plans to launch first liquid biopsy test, Oncotype SEQ™, a blood-based mutation panel that uses next-generation sequencing to identify select actionable genomic alterations for the treatment of patients with late-stage lung, breast, colon, melanoma, ovarian or gastrointestinal cancer, in mid-2016. Oncotype SEQ represents the first of several liquid biopsy tests that Genomic Health plans to deliver through the introduction of its Oncotype IQ™ Genomic Intelligence Platform.
  • Urology published a meta-analysis of the original Oncotype DX clinical validation studies demonstrating the ability of the Genomic Prostate Score (GPS) to refine risk stratification for low- and intermediate-risk patients with greater precision compared to clinical classifiers alone.
  • Positive results from a large prospective outcomes study in Germany were accepted for publication in the Journal of Clinical Oncology. Led by the Women’s Healthcare Study Group, the PlanB study demonstrated that women with breast Recurrence Score® results of 11 or less who were treated with hormonal therapy alone had excellent outcomes with 98 percent disease-free survival rates at three years despite having intermediate- or high-risk disease by traditional parameters.
  • Received acceptance to present five year outcomes data from the PlanB study in an oral presentation at the upcoming European Breast Cancer Conference in March.
  • Announced results from multiple Oncotype DX breast cancer test studies at the 38th CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) reconfirming that Oncotype DX accurately predicts clinical outcomes – including risk of recurrence and breast cancer survival – in early-stage patients with invasive breast cancer. Data include results from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI); complete results from a multi-center study from Clalit Health Services, the largest health maintenance organization in Israel; additional analyses from the NCI-sponsored Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx; and the German PlanB study.

Conference Call Details
To access the live conference call today, February 10 at 4:30 p.m. Eastern Time via phone, please dial (877) 303-7208 from the United States and Canada or +1 (224) 357-2389 internationally.  The conference ID is 34365800.  Please dial in approximately ten minutes prior to the start of the call.  To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company’s website at http://investor.genomichealth.com/events.cfm. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world’s leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of cancer, one of the greatest issues in healthcare today. With its Oncotype IQ™ Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company’s flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 600,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid and tissue-based tests. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealthFacebookYouTube and LinkedIn.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating the company’s beliefs regarding its liquid biopsy platform and the timing of a liquid biopsy test; the company’s intent to continue its investments in DCIS, prostate cancer and international markets; the company’s full year 2015 results; the attributes and focus of the company’s product pipeline; the ability of any potential tests the company may develop to optimize cancer treatment; and the ability of the company to develop and commercialize additional tests in the future. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company’s tests; the results of clinical studies and their impact on reimbursement and adoption; the applicability of clinical study results to actual outcomes; the company’s ability to develop and commercialize new tests and expand into new markets domestically and internationally; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; the company’s ability to obtain capital when needed and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, DCIS Score, Oncotype SEQ, and Oncotype IQ are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

 

GENOMIC HEALTH, INC.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

Three Months Ended

Twelve Months Ended

December 31,

December 31,

2015

2014

2015

2014

Unaudited

Unaudited

REVENUES:

Product revenues – United States

$

63,918

$

58,794

$

245,378

$

230,657

Product revenues – Outside of the United States

10,582

10,332

41,447

45,049

Total revenues

74,500

69,126

286,825

275,706

OPERATING EXPENSES (1)(2):

Cost of product revenues

14,078

12,501

53,591

48,742

Research and development

12,605

12,549

59,798

53,076

Selling and marketing

35,593

35,144

143,557

137,846

General and administrative

15,755

14,919

64,348

59,669

Total operating expenses

78,031

75,113

321,294

299,333

Loss from operations

(3,531)

(5,987)

(34,469)

(23,627)

Interest income

58

48

221

192

Other income (expense), net

(291)

(227)

(498)

(764)

Loss before income taxes

(3,764)

(6,166)

(34,746)

(24,199)

Income tax expense (benefit)

(587)

101

(996)

393

Net loss

$

(3,177)

$

(6,267)

$

(33,750)

$

(24,592)

Basic and diluted net loss per share

$

(0.10)

$

(0.20)

$

(1.04)

$

(0.78)

Shares used in computing basic and diluted net loss per share

32,645

31,791

32,382

31,453

(1)

Included in operating expenses for the three months ended December 31, 2015 were non-cash charges of $6.0 million, including $4.0 million of stock-based compensation expense and $2.0 million of depreciation and amortization expenses, compared with non-cash charges for the same period in 2014 of $5.6 million, including $3.9 million of stock-based compensation expense and $1.7 million of depreciation and amortization expenses.

(2)

Included in operating expenses for the twelve months ended December 31, 2015 were non-cash charges of $23.1 million, including $16.0 million of stock-based compensation expense and $7.1 million of depreciation and amortization expenses, compared with non-cash charges for the same period in 2014 of $23.4 million, including $16.5 million of stock-based compensation expense and $6.9 million of depreciation and amortization expenses.

 

GENOMIC HEALTH, INC.

Condensed Consolidated Balance Sheets

(In thousands)

As of
December 31,
2015

As of
December 31,
2014

(Unaudited)

(1)

Cash and cash equivalents

$

32,533

$

29,726

Short-term marketable securities (2)

62,410

73,934

Accounts receivable, net

36,531

34,916

Prepaid expenses and other current assets

10,844

9,944

Total current assets

142,318

148,520

Property and equipment, net

39,746

21,860

Other assets

1,921

15,541

Total assets

$

183,985

$

185,921

Accounts payable

$

8,395

$

6,987

Accrued expenses and other current liabilities

33,656

31,016

Deferred revenues

431

335

Other liabilities

2,410

2,070

Stockholders’ equity

139,093

145,513

Total liabilities and stockholders’ equity

$

183,985

$

185,921

(1)

The condensed consolidated balance sheet at December 31, 2014, has been derived from the audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014.

(2)

Included in short-term marketable securities as of December 31, 2015, was $18.1 million of corporate equity securities, representing the Company’s investment in Invitae Corporation.

 

Logo – http://photos.prnewswire.com/prnh/20130425/SF01493LOGO

 

SOURCE Genomic Health, Inc.

Sr. Research Associate, Analytical Chemistry – Vertex Pharmaceuticals – San Diego, CA

February 10, 2016 – 11:37 am

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better…
From Vertex Pharmaceuticals – 10 Feb 2016 18:37:32 GMT
– View all…

Top Engineer Behind Google’s Rise Will Lead Grail In Cancer-Test Quest

February 10, 2016 – 7:53 am

Grail wants to develop a blood test that detects early stage cancer in seemingly healthy people, an ambitious and daunting proposition that I wrote about in detail last week. After a month in the…

[[Click headline to continue reading.]]

Silicon Biosystems Menarini, Swift Biosciences Announce Collaboration and Co-Marketing Partnership to Unlock Genomic Information from FFPE Samples

February 10, 2016 – 7:33 am

Alliance Combines the Power of Precise Single-Cell Isolation with Next Generation Sequencing

ORLANDO, Fla., Feb. 10, 2016 /PRNewswire/ — Silicon Biosystems Menarini Inc., a developer and manufac­turer of technologies and products that help uncover the biological complexities of disease at the single-cell level, and Swift Biosciences Inc., a developer of innovative technologies for genomics research, today announced a scientific collaboration and co-marketing partnership aimed at enabling translational researchers to obtain high-quality sequencing results from as few as a couple hundred tumor and normal cells in an optimized and seamless workflow.

Silicon Biosystems Menarini will develop new workflows focused on translational research that combines its DEPArray™ System with Swift Biosciences’ Next Generation Sequencing (NGS) technology. The announcement was made at the annual Advances in Genome Biology and Technology (AGBT) meeting held in Orlando, February 10th-13th. Both companies will present recent findings of their collaborative research on February 13th.

Tim Harkins, CEO of Swift Biosciences, explained how the combination of the two technologies enables oncology researchers to fully access genomic information locked within formalin-fixed paraffin-embedded (FFPE) tissue samples. “Working with Silicon Biosystems Menarini has revolutionized the analysis of FFPE samples by enabling researchers to perform whole genome, exome and targeted resequencing from samples that previously could not be sequenced. There is a treasure trove of genetic information in countless FFPE collections that can now be unlocked with the combination of these technologies. It is a very exciting time for the oncology community.”

Giuseppe Giorgini, CEO of Silicon Biosystems Menarini added, “Offering our DEPArray system owners the simple and optimized sequencing solution that Swift Biosciences provides will guarantee them reliable and high-quality results that translational research requires.”

Combining the Power of Precise Single-Cell Isolation with NGS
The DEPArray system is capable of isolating a few hundred matched tumor and normal cells from FFPE materials, or from frozen tumor specimens, and cell cultures. Based on the principle of dielectrophoresis, which exploits the ability of a non-uniform electric field to move cells in a spatial gradient, the system provides precise image-based cell selection for identification and sorting of individual cells, or pools of cells, at 100% purity for further genetic analysis or culturing. With Swift Biosciences’ Accel-NGS® 2S DNA Library Kits researchers are able to build complex libraries from as little as 100 pg of DNA. The new Accel-NGS 2S Hyb DNA Library Kit will allow the sequencing of whole exomes from FFPE samples that contain low amounts of damaged and fragmented DNA. The DEPArray System and Accel-Amplicon™ panels have also been optimized together to deliver somatic mutation detection in 56 clinically relevant oncology-related genes.

About Swift Biosciences
Swift Biosciences Inc. is developing innovative and enabling technologies for genomics research. The company’s Accel-NGS® product portfolio brings unique capabilities to improve the efficiency and quality of NGS sample preparation across multiple applications. The Accel-NGS library preparation kits offer high-performance sequence coverage metrics, even from challenging samples, and can generate PCR-free libraries for whole genome sequencing from as little as 10 ng of genomic input. The company’s Accel-Amplicon products encompass multiple panels that include a 56G Oncology Panel, a Sample_ID panel, and custom panels across multiple genomes. Swift Biosciences also offers kits for bisulfite-converted DNA for methylation sequencing and a product for single-stranded DNA that are ideal for viral and phage metagenomes. For more information, please visit www.swiftbiosci.com and follow Swift Biosci­ences on Twitter (@SwiftBioSci).

About Silicon Biosystems Menarini — The Single Cell-Precision Company
Silicon Biosystems Menarini Inc., based in San Diego, Calif. and Bologna, Italy, is a wholly owned subsidiary of The Menarini Group, a multinational pharmaceutical, biotechnology and diagnostics company headquartered in Florence, Italy. The company manufactures and sells the DEPArray system, which enables researchers to automatically identify, quantify, and recover individual rare cells with single-cell precision.

For more information visit http://www.siliconbiosystems.com.

 

SOURCE Silicon Biosystems Menarini Inc.

American Life Science Pharmaceuticals, Inc. (ALSP, Inc.) Appoints Col. (Retired) Dallas Hack, MD as Consultant

February 10, 2016 – 7:33 am

SAN DIEGO, Feb. 10, 2016 /PRNewswire/ — ALSP, Inc. announced that it has appointed Col.(Retired) Dallas C. Hack, MD as Consultant for Medical Affairs in preparation for its move into clinical trials with its lead drug.

Michael Pierschbacher, PhD, CEO, stated, “We are pleased to welcome Dallas Hack onto the ALSP team. We look forward to working with an individual of such practical knowledge and far-reaching experience in Traumatic Brain Injury (TBI). We look forward to drawing deeply on his broad experience and success as a clinician and researcher in this area as we enter into our next stage of growth, clinical development.”

Since 2008, Col. Dallas Hack, MD was the director of the Combat Casualty Care Research Program and Chair, Joint Program Committee 6 (Combat Casualty Care), U.S. Army Medical Research and Materiel Command, Fort Detrick, MD, coordinating leading edge-research focused on TBI. He also served as the Chair of Joint Technology Coordinating Group 6 of the Armed Services Biomedical Research Evaluation and Management (ASBREM) Committee. He has been awarded numerous medals, including the Bronze Star and Legion of Merit.

Dr. Hack graduated from Loma Linda University School of Medicine in 1976. After a rotating internship in Anesthesiology and a fellowship in Cardiology and Biomathematics, he worked in General Practice and Biomedical Engineering for 9 years, serving as Vice President of Engineering for a number of biomedical companies. He was recruited into active duty in September 1987, to modernize clinical research at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) completing a residency in General Preventive Medicine in 1995. He also has a MPH from Johns Hopkins, a Master of Strategic Studies from the U.S. Army War College, and a CPE from the Certifying Commission in Medical Management.

Dr. Hack commented, “It is an honor to join such an experienced scientific and business team who are exceptionally dedicated to pushing back the boundaries of treatments for TBI, AD and other neurodegenerative diseases. This leading-edge work is vitally important.”

About ALSP, Inc.
ALSP, Inc. is a privately held company in San Diego, California, developing small molecule drugs for treating neurodegenerative diseases, initially focused on TBI and Alzheimer’s Disease (AD).
Further  information: www.alspinc.com

Forward-Looking Statements:
This release contains “forward-looking statements” as defined under U.S. federal securities laws.

 

SOURCE American Life Science Pharmaceuticals, Inc.

Mast Therapeutics Announces Pricing Of Underwritten Public Offering

February 10, 2016 – 7:09 am

SAN DIEGO, Feb. 10, 2016 /PRNewswire/ — Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure, today announced the pricing of an underwritten public offering of 29,090,910 units at a price to the public of $0.275 per unit. Each unit consists of one share of the Company’s common stock and one warrant to purchase one share of the Company’s common stock at an exercise price of $0.42 per share. The warrants are exercisable six months and one day following issuance and have a term of exercise of five years following issuance.  The gross proceeds from this offering are expected to be approximately $8 million and, after deducting the underwriting discount and estimated offering expenses, Mast Therapeutics expects to receive net proceeds of approximately $7.3 million, not including any future proceeds from the exercise of the warrants. The offering is expected to close on or about February 16, 2016, subject to customary closing conditions.

Roth Capital Partners is acting as sole book-running manager for the offering.  Maxim Group LLC is acting as co-manager for the offering.

Mast Therapeutics intends to use the net proceeds from the offering primarily to fund its clinical development programs of vepoloxamer in sickle cell disease and vepoloxamer and AIR001 in heart failure, for regulatory, manufacturing and other commercial-readiness activities for vepoloxamer in sickle cell disease, and for working capital and general corporate purposes.

The securities described above are being offered by Mast Therapeutics pursuant to a shelf registration statement that was previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC). The securities may be offered only be means of a prospectus supplement relating to the offering and the accompanying base prospectus, which form a part of the shelf registration statement. A preliminary prospectus supplement related to the offering has been filed with the SEC. A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained from Roth Capital Partners, 888 San Clemente, Newport Beach, CA 92660, (800) 678-9147 or by accessing the SEC’s website, http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California.  The Company is leveraging its Molecular Adhesion and Sealant Technology (MAST) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop vepoloxamer (also known as MST-188), its lead product candidate, for serious or life-threatening diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes. The Company is also developing AIR001, a sodium nitrite solution for inhalation via nebulization.

Vepoloxamer is an investigational new drug being evaluated in a pivotal Phase 3 study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease and in a Phase 2 study for the treatment of patients with chronic heart failure.  AIR001 is an investigational new drug in Phase 2a clinical development for the treatment of patients with heart failure with preserved ejection fraction (HFpEF). More information can be found on the Company’s web site at www.masttherapeutics.com. (Twitter: @MastThera

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the Company’s current expectations and assumptions. Such forward-looking statements may be identified by the use of forward-looking words such as “intend,” “plan,” “anticipate,” “believe,” “expect,” among others, and include, but are not limited to, statements relating to the closing of public offering of the Company’s securities and the Company’s intended use of proceeds from the offering.  There are a number of factors that could cause or contribute to material differences between actual events or results and the expectations indicated by the forward-looking statements. These factors include, but are not limited to: market and other conditions that affect whether and when the public offering may be completed; the inherent uncertainty of outcomes in ongoing and future studies of the Company’s product candidates and the risk that its product candidates, including vepoloxamer, may not demonstrate adequate safety, efficacy or tolerability in one or more such studies, including EPIC; delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a “clinical hold,” and/or suspension or termination of a clinical study, including due to patient safety concerns or lack of funding; delays in clinical study closeouts, including blinded data review and quality assurance procedures; the risk that, even if current and planned clinical studies are successful, the FDA or other regulatory agencies may determine they are not sufficient to support a new drug application; the potential that, even if clinical studies of a product candidate in one indication are successful, clinical studies in another indication may not be successful; the Company’s dependence on third parties to assist with important aspects of development of its product candidates, including conduct of its clinical studies and supply and manufacture of clinical trial material, and, if approved, commercial product, and the risk that such third parties may fail to perform as expected; the risk that the Company may be required to repay its outstanding debt obligations on an accelerated basis and/or at a time that could be detrimental to its financial condition, operations and/or business strategy; risk associated with the Company’s ability to manage operating expenses and/or obtain additional funding to support its operations on a timely basis or on acceptable terms, or at all; the potential for the Company to delay, reduce or discontinue current and/or planned development activities, including clinical studies, or partner its product candidates at inopportune times if it is unable to raise sufficient additional capital as needed; the risk that, even if the Company successfully develops a product candidate in one or more indications, it may not realize commercial success and may never achieve profitability; the risk that the Company is not able to obtain and maintain effective patent coverage or other market exclusivity protections for its products, if approved, without infringing the proprietary rights of others; and other risks and uncertainties more fully described in the Company’s press releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Mast Therapeutics does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law. 

Logo – http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a

 

SOURCE Mast Therapeutics, Inc.

Scientist II – GMP (Sorrento Valley)

February 10, 2016 – 5:53 am

We are seeking a Scientist II to execute product and manufacturing process improvements. Candidates should have experience working in a GMP environment.
? Plans and executes own experimental work
? Analyzes associated lines of investigation and dev […

Sr. Systems Engineer – Ajinomoto Althea, Inc. – San Diego, CA

February 10, 2016 – 2:04 am

Is a fully integrated contract development and manufacturing organization providing clinical drug process development and manufacturing services to global…
From Ajinomoto Althea, Inc. – 10 Feb 2016 09:04:12 GMT
– View all San…

Sr Staff Scientist – Molecular Dx Product Development – Illumina, Inc. – San Diego, CA

February 9, 2016 – 11:17 pm

Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe….
From Illumina, Inc. – 10 Feb 2016 06:17:13 GMT
– View all San Diego jobs